Cargando…
A Patient with Corneal Epithelial Disorder That Developed after Administration of a Latanoprost Generic, but Not a Brand-Name Drug, Eye Drop
Background. We report a patient who developed corneal epithelial disorder repeatedly after changing the prescription from Xalatan eye drops (Pfizer Inc.) to Latanoprost eye drops (Kaken Pharmaceutical Co., Ltd.), both containing 0.005% latanoprost. Case Report. An 88-year-old male with glaucoma had...
Autores principales: | Takada, Yukihisa, Okada, Yuka, Fujita, Norihito, Saika, Shizuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467777/ https://www.ncbi.nlm.nih.gov/pubmed/23082262 http://dx.doi.org/10.1155/2012/536746 |
Ejemplares similares
-
Brand Name Versus Generic?
por: Aungaroon, Gewalin
Publicado: (2023) -
A Case of Solitary Nonvascularized Corneal Epithelial Dysplasia
por: Morii, Tomoya, et al.
Publicado: (2016) -
Therapeutic Penetrating Keratoplasty in a Case of Corneal Perforation Caused by Colletotrichum gloeosporioides Infection
por: Imai, Kazuki, et al.
Publicado: (2022) -
Severe Cutaneous Reaction to Latanoprost Eye Drops
por: Yip, Ivan Yeu Ming, et al.
Publicado: (2018) -
The concept of: Generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs
por: Thakkar, Karan B., et al.
Publicado: (2013)